HTB http://i-base.info/htb HIV treatment research reports Fri, 10 Feb 2012 22:44:24 +0000 http://backend.userland.com/rss092 en 2nd International Workshop on HIV & Women, 9-10 January 2012, Bethesda, USA http://i-base.info/htb/16128 Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks http://i-base.info/htb/16126 Volume 13 Number 1/2 January/February 2012 http://i-base.info/htb/16024 The effect of BMI on efficacy, safety and tolerability of lopinavir/r in women http://i-base.info/htb/16124 Hormonal contraception and higher risk of non-AIDS-defining events in Nashville cohort http://i-base.info/htb/16122 Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes http://i-base.info/htb/16119 5th HIV Persistence Workshop on HIV Reservoirs, 6-9 December 2011, West Indies http://i-base.info/htb/16116 Workshop report and commentary http://i-base.info/htb/16112 Nevirapine prolonged release (PR) once-daily formulation available in the UK http://i-base.info/htb/16110 Etravirine 200 mg formulation available in UK http://i-base.info/htb/16108 Tenofovir label extended to paediatric indication http://i-base.info/htb/16106 FDA approve US paediatric dose for raltegravir http://i-base.info/htb/16103 FDA approve paediatric dose for darunavir http://i-base.info/htb/16101 Efavirenz dose increase to 800 mg QD with rifampin in patients >50 kg http://i-base.info/htb/16098 FDA approval of generic ARVs http://i-base.info/htb/16096 Disastrous warning for global HIV programmes in 2012 http://i-base.info/htb/16094 Janssen block Patent Pool access to darunavir, rilpivirine and etravrine http://i-base.info/htb/16092 UNITAID continues funding the Patent Pool, paediatric HIV medicines and malaria http://i-base.info/htb/16089 Michel Kazatchkine resigns from Global Fund: Gabriel Jaramillo, Brazilian banker, to serve as general manager http://i-base.info/htb/16087 Call to Action on Global Fund restriction to new funding to 2014 http://i-base.info/htb/16084 Analysis of why the Global Fund cancelled Round 11 http://i-base.info/htb/16082 Reaction to the Global Fund’s decisions on Round 11 and grant renewals http://i-base.info/htb/16078 Activists oppose Gates Foundation funding study using low dose d4T http://i-base.info/htb/16076 Delaying ART in childhood can reduce long-term CD4 count in adulthood http://i-base.info/htb/16073 No increased risk of non-AIDS deaths from cumulative use of ART in EuroSIDA cohort http://i-base.info/htb/16071 Need for expanded access to two promising MDR TB drugs http://i-base.info/htb/16069 Interactions between nevirapine and antimalarials (artemether and lumefantrine) http://i-base.info/htb/16067 Interactions between antiretrovirals and complementary and African traditional medicines http://i-base.info/htb/16065 Drug interactions between sirolimus (rapamycin) and ARVs http://i-base.info/htb/16063 Supplement: HIV testing and risks of sexual transmission http://i-base.info/htb/16029 Draft BHIVA ARV treatment guidelines online for comment until 5 March http://i-base.info/htb/16058 Contraceptive failure with etonogestrel implants and efavirenz: case reports http://i-base.info/htb/16060 BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011 http://i-base.info/htb/16056 Draft BHIVA pregnancy guidelines online for comment until 5 March http://i-base.info/htb/16155 NICE guidance on increasing the uptake of HIV testing http://i-base.info/htb/16053 London Commissioning: new announcements http://i-base.info/htb/16051 Testosterone: A man’s guide: practical tips for boosting physical, mental and sexual vitality; by Nelson Vergel http://i-base.info/htb/16049 2011 HIV Persistence Workshop http://i-base.info/htb/16047 A Call for Comprehensive Responses to HIV in People Who Use Drugs http://i-base.info/htb/16045 Achieving a cure for HIV infection: do we have reasons to be optimistic? http://i-base.info/htb/16041 2012 conference listing http://i-base.info/htb/101 Volume 13 Number 1/2 January/February 2012 PDF http://i-base.info/htb/16018 13th European AIDS Conference (EACS), Belgrade, Serbia, 12–15 October 2011 http://i-base.info/htb/15966 European guidelines (EACS) – 2011 update http://i-base.info/htb/15964 Raltegravir achieves superiority over efavirenz after four years http://i-base.info/htb/15961 Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients http://i-base.info/htb/15959 Ritonavir levels reduced with high fat meal http://i-base.info/htb/15957 Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates http://i-base.info/htb/15955 2nd International Workshop on HIV and Ageing, Baltimore, Maryland, 27–28 October 2011 http://i-base.info/htb/15953 Statin blocks negative impact of PIs on bone formation in vitro http://i-base.info/htb/15951 HIV linked to frailty in middle-aged IDUs, especially with poor HIV control http://i-base.info/htb/15949 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, 17–20 September 2011 http://i-base.info/htb/15945 Volume 12 Number 11/12 November/December 2011 http://i-base.info/htb/15861 Monitoring kidney function change with cobicistat http://i-base.info/htb/15942 Intracellular raltegravir concentrations better with twice-daily than once-daily dosing http://i-base.info/htb/15939 Rilpivirine (Edurant) and rilpivirine/FTC/tenofovir FDC (Eviplera) approved in Europe http://i-base.info/htb/15936 FDA updates US label for darunavir for serious rash http://i-base.info/htb/15934 FDA updates US label for raltegravir due to serious rash http://i-base.info/htb/15932 Lopinavir concentrations suboptimal at reduced dose of lopinavir/ritonavir 200/50 mg twice daily http://i-base.info/htb/15930 Switching to 50mg ritonavir dose for selected protease inhibitors http://i-base.info/htb/15928 New formulations, acquisitions and company announcements http://i-base.info/htb/15925 Iranian doctors now freed http://i-base.info/htb/15880 New York court rejects AIDS denialist case against leading HIV community activist and journalist http://i-base.info/htb/15878 UK ban on HIV-positive doctors and dentists set to be overturned http://i-base.info/htb/15876 We Were Here http://i-base.info/htb/15873 US guidelines (DHHS) update recommendations for first-line combinations (October 2011) http://i-base.info/htb/15921 Global Fund cancels Round 11 and introduces new rules for grant renewals http://i-base.info/htb/15919 Cure research: report from research workshop http://i-base.info/htb/15864 Free full text online articles http://i-base.info/htb/15867 FDA approval of generic ARVs http://i-base.info/htb/15917 We need the Patent Pool to work http://i-base.info/htb/15915 Efavirenz under-dosing in children http://i-base.info/htb/15912 Treatment response and duration of first line treatment in European infants http://i-base.info/htb/15910 US guidelines for management of older people living with HIV http://i-base.info/htb/15907 New studies on HIV and the diseases of ageing http://i-base.info/htb/15905 Risk of cataract surgery higher in HIV-positive compared to HIV-negative people http://i-base.info/htb/15902 CD4 count <200 independently associated with 5-fold increased risk of fracture http://i-base.info/htb/15900 Exercise as immune-based therapy http://i-base.info/htb/15898 Mapping the long genetic road to broadly neutralising antibodies http://i-base.info/htb/15896 Monkey viral reservoir study goes for gold http://i-base.info/htb/15894 Immune pressure on HIV http://i-base.info/htb/15891 Lymphocyte production capacity in HIV: links to immune activation & immune reconstitution on ART http://i-base.info/htb/15889 International PrEP study (VOICE) discontinues use of tenofovir vaginal gel due to lack of efficacy http://i-base.info/htb/15887 UK Health Protection Agency (HPA) recommends universal HIV testing in the high incidence regions of the UK http://i-base.info/htb/15885 Volume 12 Number 11/12 November/December 2011 PDF http://i-base.info/htb/15853 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17–20 July 2011, Rome http://i-base.info/htb/15831 Cure research and viral reservoirs http://i-base.info/htb/15828 Orange Farm circumcision results dispel concerns about risk compensation http://i-base.info/htb/15826 Randomised trial of ART in TB patients with high CD4 counts http://i-base.info/htb/15824 Once-daily nevirapine approved in Europe http://i-base.info/htb/15821 Fixed-dose combination of rilpivirine/tenofovir/FTC (Eviplera) recommended for approval in Europe http://i-base.info/htb/15819 ViiV withdraw European application for once-daily maraviroc http://i-base.info/htb/15817 FDA approval of generic ARVs http://i-base.info/htb/15813 Increased risk of preterm delivery with protease inhibitor based HAART in Mma Bana http://i-base.info/htb/15804 Global Fund adopts restructuring recommendations and close to 50% funding shortfall for next round of grants http://i-base.info/htb/15815 Efavirenz in pregnancy: update of systemic review and meta-analysis http://i-base.info/htb/15802 AZT not equivalent to HAART to prevent mother-to-child transmission in a Botswana programme http://i-base.info/htb/15800 Increased risk of HIV transmission to HIV-negative partners during pregnancy http://i-base.info/htb/15798 Pharmacokinetics of paediatric tenofovir based regimens http://i-base.info/htb/15796 Atazanavir pharmacokinetics in infants, children and adolescents http://i-base.info/htb/15793